The Fort Worth Press - AMC Health Deepens Its Role as the Trusted Operational Partner for Decentralized Clinical Trials with the Appointment of Keith Tode as EVP

USD -
AED 3.672504
AFN 66.503991
ALL 80.629676
AMD 365.091035
AOA 917.000367
ARS 1491.937897
AUD 1.417435
AWG 1.80125
AZN 1.70397
BAM 1.691649
BBD 2.00813
BDT 123.418242
BHD 0.375989
BIF 2985.079791
BMD 1
BND 1.277602
BOB 11.849673
BRL 5.083304
BSD 0.997016
BTN 94.875232
BWP 13.457596
BYN 2.968819
BYR 19600
BZD 2.00519
CAD 1.39515
CDF 2262.50392
CHF 0.80949
CLF 0.023206
CLP 913.315746
CNY 6.747604
CNH 6.743285
COP 3142.844787
CRC 453.228387
CUC 1
CUP 26.5
CVE 95.372573
CZK 20.982104
DJF 177.546166
DKK 6.46804
DOP 58.20179
DZD 132.308956
EGP 49.555853
ERN 15
ETB 160.923669
EUR 0.86495
FJD 2.20855
FKP 0.74148
GBP 0.742583
GEL 2.610391
GGP 0.74148
GHS 11.700039
GIP 0.74148
GMD 73.503851
GNF 8756.649224
GTQ 7.607144
GYD 208.588851
HKD 7.842304
HNL 26.723176
HRK 6.518804
HTG 130.363707
HUF 314.060388
IDR 17801
ILS 2.99985
IMP 0.74148
INR 95.210504
IQD 1306.058902
IRR 1375550.000352
ISK 123.340386
JEP 0.74148
JMD 158.335856
JOD 0.70904
JPY 157.80604
KES 129.014401
KGS 87.450384
KHR 4049.647537
KMF 426.00035
KRW 1407.860383
KWD 0.30866
KYD 0.830861
KZT 467.275008
LAK 22510.919863
LBP 89282.792025
LKR 334.420274
LRD 179.959348
LSL 16.197552
LTL 2.95274
LVL 0.60489
LYD 6.341738
MAD 9.29222
MDL 17.337716
MGA 4254.638239
MKD 53.219738
MMK 2099.549369
MNT 3595.852714
MOP 8.056654
MRU 40.080439
MUR 47.070378
MVR 15.450378
MWK 1728.841413
MXN 17.380378
MYR 4.090104
MZN 63.905039
NAD 16.197552
NGN 1364.860377
NIO 36.690741
NOK 9.51237
NPR 151.800372
NZD 1.701115
OMR 0.382693
PAB 0.997016
PEN 3.376465
PGK 4.406003
PHP 60.705038
PKR 276.796523
PLN 3.719205
PYG 5928.296501
QAR 3.644596
RON 4.536304
RSD 101.492021
RUB 81.598409
RWF 1466.072741
SAR 3.744756
SBD 8.065696
SCR 14.449077
SDG 600.503676
SEK 9.480804
SGD 1.269504
SLE 24.603667
SOS 569.822255
SRD 37.866504
STD 20697.981008
STN 21.191022
SVC 8.723782
SZL 16.194265
THB 33.050369
TJS 9.197509
TMT 3.51
TND 2.929032
TRY 47.697504
TTD 6.757774
TWD 32.250604
TZS 2639.622886
UAH 44.653894
UGX 3714.050945
UYU 40.133201
UZS 11924.058297
VES 755.762404
VND 26204.5
VUV 118.557141
WST 2.733716
XAF 567.363231
XAG 0.015731
XAU 0.00023
XCD 2.70255
XCG 1.796912
XDR 0.705618
XOF 567.363231
XPF 103.152705
YER 238.403589
ZAR 16.14632
ZMK 9001.203584
ZMW 18.818492
ZWL 321.999592
  • CMSD

    -0.1600

    21.82

    -0.73%

  • CMSC

    0.0240

    21.744

    +0.11%

  • RIO

    1.4500

    101.1

    +1.43%

  • BCE

    -0.0200

    22.75

    -0.09%

  • RBGPF

    0.7600

    70.5

    +1.08%

  • GSK

    0.7900

    52.96

    +1.49%

  • RYCEF

    0.2300

    20.85

    +1.1%

  • BCC

    2.3400

    86.6

    +2.7%

  • AZN

    1.4100

    161.42

    +0.87%

  • VOD

    0.1900

    16.19

    +1.17%

  • NGG

    0.4700

    80.88

    +0.58%

  • BP

    -0.6000

    41.63

    -1.44%

  • RELX

    0.0485

    35.52

    +0.14%

  • JRI

    0.1500

    12.81

    +1.17%

  • BTI

    0.6000

    59.33

    +1.01%

AMC Health Deepens Its Role as the Trusted Operational Partner for Decentralized Clinical Trials with the Appointment of Keith Tode as EVP
AMC Health Deepens Its Role as the Trusted Operational Partner for Decentralized Clinical Trials with the Appointment of Keith Tode as EVP

AMC Health Deepens Its Role as the Trusted Operational Partner for Decentralized Clinical Trials with the Appointment of Keith Tode as EVP

As demand from sponsors and CROs for proven, large‑scale remote patient monitoring (RPM) capabilities continues to accelerate, AMC Health expands its decentralized clinical trial (DCT) program, bringing more than 20 years of real‑world RPM delivery to bear on the operational challenges that matter most to the life sciences industry.

Text size:

NEW YORK, NY / ACCESS Newswire / April 21, 2026 / AMC Health, a leader in remote patient monitoring and decentralized clinical trial services, today announced the appointment of Keith Tode as Executive Vice President of Decentralized Clinical Trials. The appointment reflects growing demand from biopharmaceutical and pharmaceutical sponsors, medical device companies, and contract research organizations (CROs) seeking an operational partner with the scale, infrastructure, and regulatory rigor required to successfully execute decentralized and hybrid clinical trials.

AMC Health has delivered remote patient monitoring programs to some of the most underserved and geographically dispersed patient populations in the United States, including rural communities where access to in‑person care remains limited. This history of large‑scale, real‑world RPM delivery positions AMC Health as a trusted operating partner for decentralized and hybrid clinical research.

Sponsors and CROs increasingly select AMC Health because the company delivers what much of the DCT market lacks: a proven operating partner, not simply a technology platform, point solution, or software vendor. With more than two decades of experience delivering RPM programs at scale across complex, regulated environments and broad patient populations, AMC Health brings a depth of clinical and operational experience that translates directly to modern clinical trial execution.

AMC Health's decentralized clinical trial capabilities are trusted by leading global life sciences organizations, with experience supporting studies and programs for well‑recognized sponsors and partners, including Genentech, GSK, IQVIA, and Biogen. This experience underscores AMC Health's ability to operate at enterprise scale while meeting the rigorous expectations of top‑tier pharmaceutical and clinical research organizations.

"Sponsors and CROs come to AMC Health because they need a partner who has already solved the hard operational problems," said Nesim Bildirici, Chief Executive Officer of AMC Health. "Our 20‑year history of delivering RPM programs at scale is what differentiates us in the decentralized clinical trial market, and the growing demand we're seeing from the life sciences industry confirms that."

Proven Operations. Clinical‑Grade Infrastructure. Immediately Deployable.

AMC Health's decentralized clinical trial program is not a new offering; it is the formalization and expansion of capabilities that sponsors and CROs have already relied upon in active studies. The company has supported decentralized and hybrid trials across therapeutic areas and study designs, delivering the operational infrastructure required to keep trials on protocol, on timeline, and on budget.

Together, these capabilities form a fully integrated operating infrastructure designed to remove execution risk from decentralized and hybrid trials, including:

Clinical-grade RPM operations using FDA Class II-cleared connected devices and wearables, supported by a 24/7 monitoring center

GCP‑compliant virtual trial infrastructure, including telehealth facilitation, eConsent, eCOA/PRO capture, and 21 CFR Part 11-compliant platforms

Enterprise-level privacy and security, anchored by HITRUST Certification

Patient engagement and retention, delivered through a nationwide, nurse‑led virtual medical home network

End‑to‑end device logistics, from procurement and configuration to deployment and retrieval at scale

AMC Health's modular engagement model is designed to align with how clinical research teams actually operate and has driven rapid adoption across sponsors and CROs supporting decentralized and hybrid studies.

Leadership to Support Continued Growth

As Executive Vice President of Decentralized Clinical Trials, Keith Tode brings extensive experience across the life sciences industry, having held senior leadership roles at PAREXEL, MCRA (an IQVIA company), Cardiovascular Clinical Sciences, and Thomson Reuters Life Sciences. His career has focused on scaling operations across complex regulatory environments, digital health platforms, and emerging technologies, with a consistent emphasis on expanding patient access and participation across pharmaceutical, biotechnology, and medical device development.

"Throughout my career, I've worked at the intersection of operations, regulatory strategy, and digital health," said Keith Tode. "Sponsors and CROs consistently struggle to find partners who can bring all of those elements together at scale. AMC Health does exactly that."

A Track Record Sponsors and CROs Can Verify

AMC Health's credibility in the clinical research market is grounded in a recognized operational history supporting some of the most demanding healthcare programs in the country. Long‑standing partnerships with the U.S. Department of Veterans Affairs, major national and regional payers, and major health systems reflect institutional trust earned through consistent performance, rigorous compliance, and clinical excellence.

When sponsors or CROs engage AMC Health, they are not onboarding a new entrant to the DCT market. They are partnering with an organization that has spent decades building the clinical infrastructure, regulatory expertise, and operational discipline required to support decentralized clinical research.

About AMC Health

AMC Health is a remote patient monitoring and decentralized clinical trial services company with more than 20 years of proven operational experience. Trusted by sponsors and CROs across the life sciences industry, as well as leading healthcare organizations including the U.S. Department of Veterans Affairs, major national and regional payers, and major health systems, AMC Health delivers modular RPM and DCT operating‑partner services. These capabilities support fully remote and hybrid clinical trial designs.

AMC Health is the partner of choice for sponsors and CROs who demand proven capabilities, clinical‑grade infrastructure, and a validated track record of results. For more information, visit www.amchealth.com.

Contact Information

Gary Feiner
Director of Marketing
[email protected]
(877) 262-2240

SOURCE: AMC Health



View the original press release on ACCESS Newswire

M.McCoy--TFWP